Denali Therapeutics (NASDAQ:DNLI) Trading Up 3.6%

Denali Therapeutics Inc. (NASDAQ:DNLI) was up 3.6% during mid-day trading on Wednesday . The company traded as high as $21.72 and last traded at $21.72. Approximately 198,273 shares changed hands during trading, a decline of 83% from the average daily volume of 1,178,538 shares. The stock had previously closed at $20.96.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on DNLI shares. Stifel Nicolaus dropped their price target on shares of Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a report on Wednesday, May 8th. Wedbush dropped their price target on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, May 8th. UBS Group dropped their price target on shares of Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, April 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $95.00 price target on shares of Denali Therapeutics in a report on Wednesday, May 8th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $40.22.

Denali Therapeutics Stock Up 2.0 %

The business’s fifty day moving average is $20.27 and its 200-day moving average is $19.25.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Tuesday, May 7th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. During the same quarter in the prior year, the firm posted ($0.80) EPS. As a group, analysts expect that Denali Therapeutics Inc. will post -2.78 EPS for the current year.

Insiders Place Their Bets

In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $22.12, for a total transaction of $663,600.00. Following the sale, the director now owns 34,404 shares in the company, valued at approximately $761,016.48. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Jennifer E. Cook sold 1,458 shares of Denali Therapeutics stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $21.73, for a total transaction of $31,682.34. Following the sale, the director now owns 20,038 shares in the company, valued at $435,425.74. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $22.12, for a total transaction of $663,600.00. Following the sale, the director now owns 34,404 shares in the company, valued at approximately $761,016.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 33,812 shares of company stock worth $740,745. Company insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. CWM LLC increased its position in Denali Therapeutics by 216.7% in the fourth quarter. CWM LLC now owns 2,011 shares of the company’s stock worth $43,000 after purchasing an additional 1,376 shares during the last quarter. GAMMA Investing LLC increased its position in Denali Therapeutics by 879.5% in the second quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock worth $48,000 after purchasing an additional 1,847 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Denali Therapeutics by 48.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after purchasing an additional 807 shares during the last quarter. Fisher Asset Management LLC bought a new stake in Denali Therapeutics in the fourth quarter worth $59,000. Finally, Assetmark Inc. increased its position in Denali Therapeutics by 65.3% in the fourth quarter. Assetmark Inc. now owns 3,550 shares of the company’s stock worth $76,000 after purchasing an additional 1,402 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.